The Role of Biotechnology in Developing Treat...

The Role of Biotechnology in Developing Treatments for Rare Metabolic Disorders

Author Name : Meeti Ashesh Shah, Dr. Tejal Mehta, Dr. Gopal Natesan

ABSTRACT Approximately, there are more than 1300 known metabolic diseases according to the latest update all over the world and collectively they represent a significant cause of illness and disability in children. Approximately 7,000 rare diseases affect millions of individuals in India. There are now opportunities to accelerate the development of drugs for treating rare diseases. This review explores current advancements in drug discovery strategies for small molecules and biological approaches targeted at orphan diseases. These rare metabolic disorders are generally due to genes which are also known as Genetic Disorders; hence, employing “Biotechnology” to develop treatments and using whole genome sequencing to identify the etiologies for such diseases are appropriate strategies to exploit. There are several strategies for developing drugs for rare metabolic disorders, including Target Identification and Validation, Gene Therapy, Enzyme Replacement Therapy, Substrate Reduction Therapy, Small Molecule Drugs Therapies (e.g., substrate reduction, chemical chaperone, cofactor, expression modification, and read-through therapies), Biologics, Personalized Medicine, Cell and Gene Editing Technologies, Regulatory and Clinical Pathway Optimization, Collaborative Networks and Patient Engagement. Each strategy has its own strengths and limitations in drug development. Furthermore, recent research into rare diseases, such as inherited immunodeficiency’s and metabolic disorders, has not only improved outcomes for patients but has also provided significant insights into biological mechanisms relevant to more prevalent conditions. This review underscores the vital role of collaboration among academic institutions, pharmaceutical companies, patient advocacy groups, and society in advancing our understanding of rare diseases.